Selected article for: "CoV infection and cytokine storm"
Author: Yu, Wen-Liang; Toh, Han Siong; Liao, Chia-Te; Chang, Wei-Ting
Title: A Double-Edged Sword—Cardiovascular Concerns of Potential Anti-COVID-19 Drugs
  • Cord-id: 4361psuq
  • Document date: 2020_6_17
    • ID: 4361psuq
    Snippet: Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Seve
    Document: Coronavirus disease 2019 (COVID-19) is a pandemic infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). COVID-19 significantly affects multiple systems including the cardiovascular system. Most importantly, in addition to the direct injury from the virus per se, the subsequent cytokine storm, an overproduction of immune cells and their activating compounds, causes devastating damage. To date, emerging anti-SARS-CoV-2 treatments are warranted to control epidemics. Several candidate drugs have been screened and are currently under investigation. These primarily include antiviral regimens and immunomodulatory regimens. However, beyond the anti-SARS-CoV-2 effects, these drugs may also have risks to the cardiovascular system, especially altering cardiac conduction. Herein, we review the cardiovascular risks of potential anti-COVID-19 drugs.

    Search related documents:
    Co phrase search for related documents
    • active metabolite and lopinavir ritonavir: 1
    • active site and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • active site and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • active site and low density: 1
    • acute respiratory and long congenital: 1
    • acute respiratory and long congenital qt: 1
    • acute respiratory and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lopinavir treat: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory and low consider: 1, 2
    • acute respiratory and low density: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and low density lipoprotein cholesterol: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory and low starting dose: 1
    • acute respiratory and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory and lymphatic filariasis: 1, 2, 3, 4
    • lopinavir ritonavir and low density: 1, 2
    • lopinavir ritonavir and low density lipoprotein cholesterol: 1
    • low consider and lymph node: 1
    • low density and lymph node: 1, 2